Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06743649 in Gout Subjects
NCT02187029Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06743649 in gout (4 arms), sponsored by Pfizer. Primary endpoints: Baseline of Serum Uric Acid, Percent Change From Baseline in Serum Uric Acid Level at Day 14 and 4 more. Started Jul 2014; status: terminated.
02
Drugs
PF-06743649
03
Conditions
gout
Beyond the preview
Go deeper on NCT02187029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187029.